Compare Crispr Therapeutics AG (CRSP) vs 8x8 Inc (EGHT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs 8x8 Inc — how do they compare? Crispr Therapeutics AG trades at $50.8 (market cap $4.97B), while 8x8 Inc trades at $2.17 (market cap $309.09M). The key difference: Crispr Therapeutics AG is far larger — about 16.1× 8x8 Inc's market cap, and 8x8 Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | EGHT | |
|---|---|---|
Market Cap | $4.97B | $309.09M |
Sector | Health | Technology |
52-Week High | $76.78 | $2.76 |
52-Week Low | $44.34 | $1.59 |
Enterprise Value | $3.32B | $586.76M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
EGHT trades at $2.22, up 8.29% with strong technical momentum and bullish moving averages. The company shows improving fundamentals with three consecutive quarterly EPS beats and projected profitability in 2026. Recent product innovations in AI routing and workforce management demonstrate growth potential, though high P/E ratio of 218 and negative net income require careful valuation assessment.
EGHT presents a turnaround story with improving earnings momentum and AI-driven product expansion, but faces significant execution risks amid high valuation multiples. The stock's technical strength contrasts with fundamental challenges, requiring balanced risk-reward evaluation for investors seeking growth opportunities in communications technology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About 8x8 Inc
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →
